Algeta ASA : Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's Board of Directors

Algeta ASA : Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members
                        of Algeta's Board of Directors

Oslo, Norway, 12 April 2013 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, is very pleased to
announce that Mrs Hilde Furberg and Mr Paolo Pucci were elected as new
Non-executive members of its Board of Directors at the Company's annual
general meeting held in Oslo on 11 April 2013.

Hilde Furberg (born  1958) has 30  years of experience  in the  pharmaceutical 
industry. She is currently Senior Vice President Rare Disease EMEA at  Genzyme 
(Sanofi), which she joined in 2002. She opened the first operation for Genzyme
in the Nordic region and has also had management responsibility for Genzyme in
the BeneLux region. Prior to Genzyme, Mrs Furberg spent 15 years at Baxter  in 
various business  roles  of  increasing  seniority.  She  is  a  Non-executive 
Director on the Board of Clavis Pharma ASA and is a board member of Copenhagen
Capacity. Previous board  memberships include Probi  AB and Pronova  Biopharma 
ASA (until the acquisition by BASF).

Mrs Furberg holds a Master of  Science degree in Nuclear Analytical  Chemistry 
from the University  of Oslo. She  is a  Norwegian citizen and  resides in  de 
Naarden, Netherlands.

Mrs Furberg holds  200 shares and  no options in  Algeta ASA and  she has  not 
worked as a consultant for the Company.

Paolo Pucci (born 1961) is Chief Executive Officer and member of the Board  of 
Directors of  ArQule  Inc.,  a  US-based,  Nasdaq-listed  cancer  therapeutics 
company, which he joined in 2008. Before this, Mr Pucci was at Bayer AG, where
he  held   sequential   responsibilities   as   Country   Head   Bayer   Italy 
Pharmaceuticals, President & SVP Bayer Pharmaceuticals North America -  Global 
Specialty Pharmaceuticals, and member  of the Bayer Pharmaceuticals  Executive 
Committee. He concluded  his tenure  at Bayer as  President in  charge of  the 
Bayer-Schering  Pharmaceuticals   Global   Oncology/Specialized   Therapeutics 
Business Units  and  was  instrumental in  building  Bayer's  global  oncology 
franchise for Nexavar^®. Prior to this, Mr Pucci held positions of  increasing 
responsibility with  Eli Lilly  between 1992  and 2001,  culminating with  his 
appointment  as  Managing  Director,  Eli   Lilly  Sweden  AB.  Mr  Pucci   is 
Non-executive Director on the Board of Dyax, Inc.

Mr Pucci holds an MBA from the University of Chicago and is a graduate of  the 
Universita Degli Studi  Di Napoli  in Naples, Italy.  Mr Pucci  is an  Italian 
citizen and resides in Boston, MA, USA.

Mr Pucci holds no shares and no options in Algeta ASA and he has not worked as
a consultant for the Company.

Stein Holst  Annexstad,  Algeta's Chairman,  said:  "We are  very  pleased  to 
welcome Hilde and Paolo to the Algeta Board. Between them, they have a  wealth 
of experience in the global pharma  industry and particularly in the  clinical 
and commercial development  of innovative targeted  cancer therapies. We  look 
forward to the valuable contributions they will make to the further growth and
development of  Algeta.  We would  also  like to  thank  Ingrid Wiik  and  Joe 
Anderson, who stepped down from  the Board at the  AGM, for their efforts  and 
input over their respective periods with the Company."


For further information, please contact:

Mike Booth / Renate Birkeli          +47 23 00 67 32
Communications & Corporate Affairs
Media enquiries:
Mark Swallow                         +44 207 638 9571
Citigate Dewe Rogerson     
Knut Ekern                           +47 22 04 82 00
Gambit Hill & Knowlton     
Kari Watson                          +1 781 235 3060
MacDougall Biomedical Communications 
US investor enquiries:
Tricia Swanson                       +1 646 378 2953
The Trout Group            

About Algeta

Algeta is  a  company  focused  on developing  novel  targeted  therapies  for 
patients with cancer based on  its alpha-pharmaceutical platform. The  Company 
is headquartered in  Oslo, Norway, and  has a US  subsidiary, Algeta US,  LLC, 
based in Cambridge, MA performing  commercial marketing operations in the  US. 
Algeta is  listed  on the  Oslo  Stock  Exchange (Ticker:  ALGETA).  For  more 
information please visit

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.